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Abstract
Background: Exercise referral schemes (ERS) aim to identify inactive adults in the primary care setting. The primary
care professional refers the patient to a third party service, with this service taking responsibility for prescribing and
monitoring an exercise programme tailored to the needs of the patient. This paper examines the cost-effectiveness
of ERS in promoting physical activity compared with usual care in primary care setting.
Methods: A decision analytic model was developed to estimate the cost-effectiveness of ERS from a UK NHS
perspective. The costs and outcomes of ERS were modelled over the patient’s lifetime. Data were derived from a
systematic review of the literature on the clinical and cost-effectiveness of ERS, and on parameter inputs in the
modelling framework. Outcomes were expressed as incremental cost per quality-adjusted life-year (QALY).
Deterministic and probabilistic sensitivity analyses investigated the impact of varying ERS cost and effectiveness
assumptions. Sub-group analyses explored the cost-effectiveness of ERS in sedentary people with an underlying
condition.
Results: Compared with usual care, the mean incremental lifetime cost per patient for ERS was £169 and the
mean incremental QALY was 0.008, generating a base-case incremental cost-effectiveness ratio (ICER) for ERS at
£20,876 per QALY in sedentary individuals without a diagnosed medical condition. There was a 51% probability
that ERS was cost-effective at £20,000 per QALY and 88% probability that ERS was cost-effective at £30,000 per
QALY. In sub-group analyses, cost per QALY for ERS in sedentary obese individuals was £14,618, and in sedentary
hypertensives and sedentary individuals with depression the estimated cost per QALY was £12,834 and £8,414
respectively. Incremental lifetime costs and benefits associated with ERS were small, reflecting the preventative
public health context of the intervention, with this resulting in estimates of cost-effectiveness that are sensitive to
variations in the relative risk of becoming physically active and cost of ERS.
Conclusions: ERS is associated with modest increase in lifetime costs and benefits. The cost-effectiveness of ERS is
highly sensitive to small changes in the effectiveness and cost of ERS and is subject to some significant uncertainty
mainly due to limitations in the clinical effectiveness evidence base.
Background
Insufficient physical activity is an important public
health issue in England as it is associated with an
increased risk of developing over 20 health conditions
including coronary heart disease (CHD), cancer, dia-
betes, and stroke [1-4] and is rated among the top ten
leading causes of death in high-income countries [5]. In
England, physical inactivity is estimated to cost the
economy around 8.3 billion pounds annually, of which
between 1 and 1.8 billion pounds is associated with the
treatment of physical inactivity related diseases [6]. In
spite of the negative impacts of physical inactivity, only
39% of men and 29% of women in England reported
meeting the recommended level to be considered ‘physi-
cally active’, as defined by guidance from the Chief
Medical Officer, whilst based on accelerometer data,
only 6% of men and 4% of women met the recom-
mended level [7].
Over the past decade, exercise referral schemes (ERS)
have become one of the most common interventions
used to promote physical activity in primary care [8,9].
In an ERS, people who are sedentary and/or have risk
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factor(s) for conditions known to benefit from physical
activity (e.g. high blood pressure) are referred by a pri-
mary care professional to a third party service (often a
sports centre or leisure facility), which then prescribes
and monitors an exercise programme tailored to the
individual needs of the patients [9].
To date, there is limited evidence on the cost-effec-
tiveness of ERS. A systematic review identified four pre-
vious economic evaluations [10]. These comprised three
trial-based economic evaluations of ERS [11-13] and one
model-based evaluation [8] of the cost-effectiveness of
brief interventions in primary care to promote physical
activity, including ERS. Whilst the evidence base sug-
gests that exercise referral is a cost-effective intervention
in sedentary but otherwise healthy populations there are
a number of shortcomings associated with the evidence.
First, as the authors of each of the studies acknowledge,
there is significant uncertainty around estimates of cost-
effectiveness, mainly due to limitations in the effective-
ness evidence. Second, the evidence tends to focus on
sedentary but otherwise healthy individuals, while a
number of individuals are currently referred to an ERS
with a diagnosed condition, such as coronary heart dis-
ease or depression [14].
This paper aims to examine the cost-effectiveness of
ERS in promoting physical activity compared to usual
care in a primary care setting. Our analysis uses pre-
vious research as a point of departure, and builds on
this through use of evidence synthesis and through
further analysis of the cost-effectiveness of ERS in indi-
viduals with pre-existing conditions, which is intended
to reflect the use of ERS in practice in the UK.
Methods
Modelling approach
A decision analytic model was developed to examine the
cost effectiveness of ERS. The model considers a cohort
of individuals who are exposed to ERS compared to a
control group with no ERS. The modelling framework
estimates the likelihood of becoming physically active
and examines the effects of physical activity/inactivity
on the development of conditions which are known to
be associated with level of physical activity. Specifically,
the model considers the impact of ERS on the develop-
ment of coronary heart disease, stroke and type II dia-
betes. Whilst many other conditions are thought to be
associated with physical activity, these three conditions
were selected on the basis that there is robust quantifi-
able evidence on the relationship between physical activ-
ity and their incidence [15]. Figure 1 illustrates the
model structure, which is a based on a previously devel-
oped policy-relevant cost-effectiveness model [8]. This
structure was reviewed against best practice principles
for economic modelling and considered suitable [10].
Population
The model considers a cohort of individuals, aged
between 40-60 years, who present in a sedentary state.
The age of the population was selected to reflect the
evidence on the effectiveness of ERS [10].
Perspective and time horizon
The model adopts an NHS and personal social services
perspective (third-party payer perspective), as used by
the National Institute for Health and Clinical Excellence
Figure 1 Diagram of model structure.
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(NICE) in it’s reference case for cost-effectiveness analy-
sis in health technology appraisal [2]. A lifetime time
horizon is adopted to capture future costs and to
acknowledge the benefits of physical activity. Future
costs and benefits are discounted at a rate of 3.5% per
annum [2].
Intervention and comparator
ERS was assumed to take the form of a structured pro-
gramme of exercise based in a leisure centre incorporat-
ing monitoring of individual performance, as is mainly
the case in current practice [10]. Individuals are
assumed to have been referred to the scheme by a pri-
mary care professional. The comparator was usual care
in a primary care setting. It should be acknowledged
that individuals who are not exposed to ERS may choose
to become physically active.
Effectiveness of ERS/comparator
Evidence of the effectiveness of ERS, compared with
usual care, measured in terms of the probability of mov-
ing from a sedentary state to an active state, was derived
from the meta-analysis conducted as part of a recent
review of the effectiveness literature for ERS [10]. This
was based on ‘intention-to-treat’ analyses, which
adjusted for attrition, and showed ERS to be associated
with a higher probability (relative risk (RR): 1.11; 95%
CI: 0.99, 1.25) of being active compared with usual care.
The active state is defined in line with the effectiveness
literature and physical activity for health guidance [16] i.
e. doing at least 90-150 min of at least moderate inten-
sity physical activity per week. Thus, a sedentary lifestyle
corresponds not only to non-participation in physical
activity but also to participation below the requisite
amount. The active state is assumed to last long enough
to enable health benefits to be obtained, although this
remains undefined given the inadequate evidence on the
dose response relationship between the number of years
being physically active and the incidence of long-term
outcomes. Previous analyses of behaviour change have
referred to this scenario as ‘fully engaged’ [17] to
describe an individual who makes lasting changes to
their lifestyle following an intervention.
Risks of developing health states associated with
inactivity
Evidence of the effect of physical activity on the devel-
opment of the outcomes considered in the model
(CHD, stroke and type II diabetes) is derived from a sys-
tematic review [8] and from the Health Survey for Eng-
land (HSE) 2006 (survey year focused on cardiovascular
disease and risk factors). HSE is the main data source
on morbidities in England [18]. The probability of devel-
oping CHD, stroke or type II diabetes among sedentary
individuals is generated from the prevalence of these
conditions in that population, using the HSE 2006 data
to inform these probabilities (Table 1). The probability
of developing the health states among active individuals
are derived using RR estimates identified from literature
review [8,19,20] and subsequent adjustment (dividing
the probabilities for the sedentary population by the RR
from the literature) of the probability for each condition
in the ERS cohort. The physical activity levels and study
population used to measure the RR estimates match
those of the cohort under consideration in this study.
ERS/intervention costs
The cost of the ERS intervention was derived from pre-
viously published research identified as part of a recently
published systematic review [10] which identified a
detailed micro-level costing exercise for a leisure centre
based ERS [12]. Isaacs et al. [12] reported resource use
in a health service/local authority that consists of provi-
sion of facilities, exercise trainers and administrative
support. Cost estimates are up-rated to 2010 prices,
using the consumer price index, for the current analyses.
The validity of the resource use and cost estimates
employed for ERS were assessed by an expert advisory
group (including clinicians, exercise scientists and health
economists) and judged to be representative of ERS
schemes in current practice. No attempt was made to
estimate a net cost of the intervention which subtracts
any cost savings that might result from ERS from the
cost of the intervention. When this was explored in
Isaacs et al. [12] and Gusi et al. [11], there was no clear
evidence of a change in health care utilisation (e.g. med-
ications, hospital or primary care) as result of the
intervention.
Treatment costs with CHD, stroke and type II diabetes
Total lifetime treatment costs were estimated using pub-
lished cost estimates (identified through a systematic
review) for the annual cost associated with CHD, dia-
betes, and stroke [8,21,22], and assumptions on age of
onset and life-expectancy combined with estimates of
the annual cost of treating an individual with the condi-
tion [15]. It was assumed that the treatment cost of
stroke, unlike the other health states was an event cost
because the direct costs associated with treatment of
stroke tend to occur once, rather than a recurring cost.
This is acknowledged as a simplification in the model,
as in reality there are likely to be acute and ongoing
costs associated with stroke.
Primary outcome measure (QALY)
The primary outcome of the economic evaluation is
expressed in terms of the incremental cost per quality-
adjusted life-year (QALY). Estimates of the QALYs
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associated with each of the conditions in the model are
derived using health state values for each condition [8,23]
and data on life-expectancy after onset of the condition
[24]. Life-expectancy is derived by applying data on aver-
age age of onset for each condition (Table 1).
Assessment of uncertainty
Uncertainty in parameter estimates was explored
through the use of deterministic and probability sensi-
tivity analyses. The deterministic sensitivity analysis
included one-way, scenario and extreme values analysis.
In addition, uncertainties around parameters considered
to be key drivers of the cost-effectiveness of ERS were
addressed simultaneously using probabilistic sensitivity
analyses (PSA). The parameters that had different unit
values in the 2 arms of the model (i.e. probability to be
active and probability to get the disease conditions)
were specified as incremental differences between the 2
arms and not absolute values. The intuition is that the
distributions of these parameters may be correlated and
hence representing them as absolute values may overes-
timate the uncertainty. The distributions and their
respective calculation of alpha and beta calculations
were based on [25]. In cases where there were no data
on standard errors the standard approach of using 10%
of mean estimates as standard error was followed [26]
The data adopted in the probabilistic analysis are
reported in Table 2.
Subgroup analyses in individuals with pre-existing
conditions
Sub-group analyses included an assessment of the cost
effectiveness of ERS in sedentary 40-60 year olds indivi-
duals with a diagnosed condition known to benefit from
physical activity. Obesity, hypertension and depression
were identified as the three most common conditions
reported with participation in ERS [14] and were
included in the analysis.
Table 1 Estimates of the inputs to the model
Input Value Data source
Probability of experiencing an outcome associated with physical activity
Probability of experiencing CHD when active 0.014 HSE [21]; Shaper et al. [19]
Probability of experiencing CHD when sedentary 0.027 HSE [21]; Shaper et al. [19]
Probability of experiencing stroke when active 0.011 HSE [21]; Herman et al. [20]
Probability of experiencing stroke when sedentary 0.015 HSE [21]; Herman et al. [20]
Probability of experiencing type II diabetes when active 0.022 HSE [21]; NICE [8]
Probability of experiencing type II diabetes when sedentary 0.044 HSE [21]; NICE [8]
Inputs used in calculating QALYs/treatment costs
Utility/health state value of being in CHD state 0.55 Kind et al. [22]; NICE [8]
Utility/health state value of being in stroke state 0.52 Kind et al. [22]; NICE [8]
Utility/health state value of being in type II diabetes state 0.7 Kind et al. [22]; NICE [8]
Utility/health state value of being in a non-disease health state 0.83 Kind et al. [22]; NICE [8]
Average age of cohort (in years) 50 HSE [18]
Average age of mortality (in years) 84 ONS [23]
Assumed average age of onset of a disease health state (in years) 55 NICE [8]
Life years remaining after onset of CHD 18.41 NICE [8]; ONS [23]
Life years remaining after onset of stroke 5.12 NICE [8]; ONS [23]
Life years remaining after onset of type II diabetes 28.13 NICE [8]; ONS [23]
Lifetime treatment costs*/QALYs associated with health states (per person)
Lifetime treatment costs associated with CHD state £17,728 NICE [8]
Lifetime treatment costs associated with stroke state £1,965 DH [22]
Lifetime treatment costs associated with type II diabetes state £50,309 Currie et al. [21]
Lifetime treatment costs associated with non-disease health state - -
QALYs associated with CHD state 9.94 Kind et al. [23]; NICE [8]
QALYs associated with stroke state 5.15 Kind et al. [23]; NICE [8]
QALYs associated with type II diabetes state 14.18 Kind et al. [23]; NICE [8]
QALYs associated with non-disease health state 17.18 Kind et al. [23]; NICE [8]
*Costs are in 2010 prices.
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Model validation
Two main procedures involving internal validation and
peer review were employed to check the validity of the
model [27]. The former consisted of simulating a series
of changes in the input values that are likely to vary the
results of the model with checks to see that the impacts
on the results are expected. For example, setting all
QALY parameters to zero, and checking if the output of
the QALYs in each arm is zero. In addition to this, the
model was replicated and compared using TreeAge and
excel software, and subject to a process of internal peer
review, including consistency checks, across the research
team. The validation process included peer review by a
modeller, unrelated to the research team, who under-
stood the complexities of the model and who was able
to scrutinise the spreadsheet of the model and the for-
mulae behind it.
Results
Estimates of effectiveness/costs of ERS
Table 3 summarises the estimates of the effectiveness of
ERS on physical activity levels and overall intervention
costs associated with ERS.
Estimates of the outcomes associated with physical
activity
Table 1 reports the derivation of the outcomes asso-
ciated with physical activity. This includes the probabil-
ity of experiencing an outcome (CHD, stroke or type II
diabetes), utility values, and life years associated with
each outcome.
The estimates of lifetime treatment costs and QALYs
for an individual in each health state are summarised in
Table 1. Among the conditions included in the model,
type II diabetes incurred the largest treatment cost and
stroke the least, although it should be noted that stroke
was considered as a one off clinical event whilst other
chronic outcomes were associated with ongoing treat-
ment costs.
Estimating the cost-effectiveness of ERS
Table 4 shows the estimated incremental cost-effective-
ness ratio (ICER) of the base-case analysis, using a cohort
of 1,000 individuals and a lifetime horizon. Total costs and
outcomes are divided by the cohort size (1,000) to gener-
ate per person estimates of costs and benefits. The ICER
was calculated with respect to the standard comparator
‘usual care’. Compared with usual care, ERS is more
expensive as it incurs additional mean lifetime costs of
£170 per person, but is more effective leading to a lifetime
mean QALY gain of 0.008 per person. The mean cost per
QALY of ERS compared with usual care is £20,876.
Deterministic sensitivity analysis
Table 5 shows the impact of the variation in parameter
estimates (one-way analysis) on the cost-effectiveness of
ERS. Assuming a less intensive ERS or more effective
ERS resulted in an ICER below £30,000 per QALY and
lower than the base-case. On the other hand, including
intervention costs to participants led to an ICER above
£30,000 per QALY, whilst a less effective ERS resulted
Table 2 Probabilistic sensitivity analysis inputs
Parameters Deterministic Standard error Distribution Alpha Beta
Incremental probability to be active 0.048 0.0048 beta 95.152 1887.181
Incremental probability to experience CHD 0.013 0.0013 beta 98.687 7492.621
Incremental probability to experience stroke 0.004 0.0004 beta 99.596 24799.4
Incremental probability to experience diabetes 0.022 0.0022 beta 97.778 4346.677
Treatment discounted cost of CHD 17728.031 1772.803 gamma 100 177.280
Treatment discounted cost of stroke 1965.165 196.517 gamma 100 19.652
Treatment discounted cost of diabetes 50309.426 5030.943 gamma 100 503.094
Discounted QALY for CHD health state 9.942 0.994 gamma 100 0.099
Discounted QALY for stroke health state 5.148 0.515 gamma 100 0.051
Discounted QALY for type II diabetes health state 14.182 1.418 gamma 100 0.142
Cost of intervention 222 37.9 gamma 34.311 6.470
Source: Briggs et al (25)
Table 3 Estimates of effectiveness and intervention costs
of ERS
Inputs Value Data source
Effectiveness
Probability of becoming active after exposure to
ERS
0.345 Pavey et al.
[10]
Probability of becoming active after exposure to
usual care
0.297 Pavey et al.
[10]
Intervention costs
Cost of the intervention per participant to the
providers
£222a Pavey et al.
[10]
aIn 2010 prices (estimates used in model)
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in ERS being dominated by usual care (negative ICER)-
that is ERS is more expensive and leads to loss of health
gains. The findings of the scenario analysis are pre-
sented in Table 5. In the worst case scenario, ERS was
dominated by the comparator. In the best case scenario,
the ICER fell to under £700 per QALY.
Probabilistic sensitivity analysis
A scatter plot of the probabilistic data, showing simu-
lated estimates of cost difference against QALY differ-
ence between ERS and usual care, is provided in Figure
2. The scatter plot shows that all the simulations gener-
ated an improved effectiveness of ERS but also at higher
cost (i.e. all points were in the north-east quadrant of
the cost-effectiveness plane). This reflects the relatively
modest uncertainty around the cost of the intervention
and assumptions about the distribution of uncertainty
around the estimates of effect size.
A judgment on the cost-effectiveness of ERS, from a
decision-maker context, will depend on the maximum
amount decision makers are willing to spend to obtain
an additional unit of effectiveness (in this case, a
QALY). This judgement can be informed through the
presentation of a cost-effectiveness acceptability curve,
as presented in Figure 3. At a threshold of £20,000 per
QALY, there is a 0.508 probability that ERS is cost-
effective. This increases to 0.879 when a threshold of
£30,000 per QALY is considered.
Subgroup analysis in individuals with pre-existing
conditions
Table 6 shows the probabilities of experiencing the
health states in the disease-specific cohorts. For each of
the conditions considered, the estimated ICER is lower
than the base case, reflecting the increased likelihood of
developing one of the morbidities considered in the
model if the individual has a pre-existing condition
(Table 7). Compared with usual care, ERS in these
cohorts remains more costly (albeit less so than in a
general population cohort). In terms of effectiveness,
ERS (compared with usual care) is more effective lead-
ing to improved QALY gains which are higher than in
the base case (ranging from 0.011 to 0.017). The cost
per QALY of ERS compared with usual care is between
£8,414 and £14,618 and thus can be considered cost-
effective at the £20,000 per QALY threshold.
Discussion
Our analysis estimates the cost-effectiveness of ERS
using a cost utility analysis framework. Our base case
Table 4 Base-case cost-effectiveness results comparing ERS with usual care
ERS Usual care Difference Incremental cost per QALY (ICER)
Lifetime total healthcare costs per persona £2,492 £2,322 £170 £20,876
Total QALYs per person 16.743 16.735 0.008
aIn 2010 prices
Table 5 Cost-effectiveness results (after deterministic sensitivity analyses) comparing ERS with usual care
Parameters/scenarios How data was adjusted for in the model Incremental
cost per person
Incremental effect
per person (QALY)
ICER
Base case analysis - £170 0.008 £20,876
Parameters
Intervention costs to
participants
Costs of intervention was varied from £222 to £342
(including costs to providers and participants)
£290 0.008 £35,652
Less intensive ERS Costs of intervention was varied from £222 to £110 £58 0.008 £7,085
Effectiveness of ERS (based on
lower limit of 95% CI)
Probability of becoming active after exposure to ERS was
varied from 0.336 to 0.294
£226 -0.001 Dominated*
Effectiveness of ERS (based
upper limit of 95% CI)
Probability of becoming active after exposure to ERS was
varied from 0.336 to 0.371
£122 0.015 £7,947
Scenarios
Worst cases of cost and
effectiveness
Worst case cost (£342) and worst case effectiveness
(0.294)
£346 -0.001 Dominated*
Best cases of cost and
effectiveness
Best case cost (£110) and best case effectiveness (0.371) £10 0.015 £679
Worst case cost and best case
effectiveness
Best case cost (£110) and worst case effectiveness (0.294) £242 0.015 £15,734
Best case cost and worst case
effectiveness
Worst case cost (£342) and best case effectiveness (0.371) £114 -0.001 Dominated*
*ERS more costly and less effective than control
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Figure 2 Cost-effectiveness plane.
 
 
Figure 3 Cost-effectiveness acceptability curve showing the probability of cost-effectiveness for ERS at varying levels of threshold.
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assumptions result in a favourable cost-effectiveness
ratio of £20,876 per QALY gained from ERS compared
to usual care. The typical cost effectiveness threshold
for UK ranges from £20,000 to £30,000 per QALY.
However, ICERs were highly sensitive to plausible varia-
tions in the relative risk for change in physical activity
and cost of ERS. The cost-effectiveness of ERS appears
to improve when targeted at individuals with a pre-
existing condition known to benefit from increased phy-
sical activity (i.e. £14,618/QALY in sedentary obese indi-
viduals, £12,834/QALY in sedentary hypertensives and
£8,414/QALY for sedentary individuals with depression).
This suggests that it might be possible to target ERS to
individuals with pre-existing conditions in whom the
payoffs/impact may be higher. However, there remain
some major uncertainties over whether the evidence
used to populate the model, derived from the meta-ana-
lysis, is applicable to these groups. There may be good
reason to believe that uptake, adherence and effective-
ness might differ according to the characteristics of the
recipients. We have attempted to adjust the model to
take into account differences in the rate of long-term ill-
nesses, but no data were identified as part of the effec-
tiveness review to allow for adjustment of the effect of
ERS in different populations. There is a pressing need
for better primary evidence to inform these
uncertainties.
Whilst our cost-effectiveness estimates suggest that
ERS is a cost effective use of National Health Service
(NHS) resources, it should be noted that the individual
level lifetime QALY gains are relatively modest (less
than 0.01 in our base case analysis). This estimate is
predicated on the evidence of effectiveness derived from
a meta-analysis [10], which has provided the most
robust estimate to date of the effectiveness of ERS com-
pared to usual care. However, it should be acknowl-
edged that the cost-effectiveness analysis is attempting
to capture lifetime benefits based on evidence of rela-
tively modest effect sizes derived from short-term stu-
dies. Any such analysis inevitably involves some
assumptions about the degree to which behaviour
change is lasting and fails to consider other health beha-
viours which may impact on long-term outcomes. The
result is that the cost-effectiveness analysis estimates
that ERS has a modest lifetime cost and a marginal life-
time QALY gain. Even small changes in the source data
used to populate the model, particularly evidence of
effect size and cost, may lead to significant changes in
the resulting ICER. This can best be illustrated through
consideration of the net benefit calculation. If we value
each QALY gained at £30,000 and accept that our analy-
sis is generating a lifetime QALY gain of approximately
0.008 in most cases, then the value of the benefits gen-
erated in monetary terms is approximately £240 which
exceeds the cost of the intervention. However, even a
modest change in the lifetime QALY gain, to 0.007
would result in the costs exceeding the benefits making
the cost-effectiveness of ERS questionable.
There are a number of limitations in the analysis that
need to be acknowledged. In some respects the analysis
Table 6 Inputs used in the subgroup analysis model
Cohort Inputs Value Data source
Obese Probability of experiencing CHD when active 0.0259 HSE [28]; Hu et al. [18]
Probability of experiencing CHD when sedentary 0.0376 HSE [28]; Hu et al. [18]
Probability of experiencing stroke when active 0.0259 HSE [28]; Hu et al. [18]
Probability of experiencing stroke when sedentary 0.0376 HSE [28]; Hu et al. [18]
Probability of experiencing type II diabetes when active 0.0756 HSE [28]; Hu et al. [18]
Probability of experiencing type II diabetes when sedentary 0.0986 HSE [28]; Hu et al. [18]
Hypertensive Probability of experiencing CHD when active 0.060 HSE [28]; Hu et al. [29]
Probability of experiencing CHD when sedentary 0.074 HSE [28]; Hu et al. [29]
Probability of experiencing stroke when active 0.060 HSE [28]; Hu et al. [29]
Probability of experiencing stroke when sedentary 0.074 HSE [28]; Hu et al. [29]
Depressive Probability of experiencing CHD when active 0.0336 HSE [28]; Surtees et al. [30]
Probability of experiencing CHD when sedentary 0.0801 HSE [28]; Surtees et al. [30]
Table 7 Cost-effectiveness results (disease specific cohorts) comparing ERS with usual care
Cohort Incremental cost per person(£) Incremental effect per person(QALY) ICER (£)
Obese £168 0.011 £14,618
Hypertensive £168 0.013 £12,834
Depressive £147 0.017 £8,414
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can be considered to be conservative as it includes only
a small number of conditions which are associated with
physical activity. The inclusion of other conditions, such
as musculoskeletal disease and mental health, are
expected to further improve the cost-effectiveness of
ERS. These conditions are excluded from the current
analysis due to limitations in the available data on the
relationship between their incidence and physical activ-
ity. Additional developments of this model to adopt a
wider perspective via the incorporation of ‘non-health’
outcomes associated with ERS slightly further improved
the cost-effectiveness of ERS to a base case ICER of
£17,032/QALY (see Pavey et al. [10] for detail). In the
analyses considering the ‘non-health’ outcomes, impacts
of PA were captured as: (a) reduced absenteeism at
work and disbenefits such as injuries and disability, and
(b) process utility directly attributable to increased exer-
cise. The former set of outcomes were obtained through
synthesis of the literature to identify estimates of the
magnitude of their associations with physical activity
[10] and accounted via a descriptive cost consequences
analysis. The process utility was included as a one-off
‘feel good’ benefit (QALY gain) associated with being
physically active, and was estimated via regression ana-
lyses using HSE 2008 data related to EQ-5D and self-
reported physical activity, with uncertainty in this esti-
mate tested via sensitivity analyses. Conversely, there are
a number of assumptions which could be considered to
be favourable to ERS, notably, the assumption relating
to the lasting effect of physical activity.
Sensitivity analyses provide some reassurance that the
net effect of these assumptions is modest and that the
incremental cost-effectiveness of ERS remains below
£30,000 per QALY under most scenarios. Furthermore,
our findings are largely consistent with previous analyses
of ERS which have suggested that ERS results in modest
increases in QALYs (via adverse health events avoided)
at a relatively low cost. Previous studies have tended to
conclude that ERS is a cost-effective use of resources,
although they too have highlighted uncertainty in evi-
dence based and the analytical framework used. Isaacs
et al. [12] presented results in the form of an incremen-
tal cost per unit change in SF-36 score, with the authors
concluding that in comparison with controls, ERS led to
an incremental cost of £19,500 per unit change in SF-36
score at 6 month follow-up. Given the outcome measure
adopted in the study it is not possible to make helpful
comparison with our own findings, although it should
be noted that this study also found only a modest
change in health status. In contrast, the study by Gusi et
al. [11] showed that ERS resulted in an incremental
QALY gain of 0.132 over a 6 month period as measured
by change in the EQ-5D, at an incremental cost of €41
per participant, generating an ICER of €311 per QALY.
The individuals in this study were obese and/or
depressed and the findings may provide further evidence
to suggest that physical activity can have process bene-
fits, i.e. health status gains (independent of other pre-
ventative effects) far greater than those suggested by our
own analysis. However, no attempt was made to ascer-
tain whether the benefits might be sustained beyond the
study period. The findings presented by NICE [8]
showed ERS compared with controls led to an incre-
mental cost per person of £25.10 and a lifetime QALY
gain of 0.31 per person equating to an incremental cost
per QALY of £81. We are inclined to relate our findings
more directly to the NICE [8] analysis because of simila-
rities in the methods used in both studies. For example,
the model used in our study was based on the model
used by NICE [8]. The analysis conducted for NICE
showed a greater QALY gain than our own findings.
This might be partially explained by the inclusion of
colon cancer as an additional outcome in the NICE
model. In addition to this, the NICE model adopted
higher estimates of the effectiveness of ERS than our
analysis (RR of becoming active of 1.60 vs 1.11 herein)
and there are differences in the handling of uptake and
adherence between the two analyses. Coupled with a
lower estimated cost of ERS this result in the NICE ana-
lysis generating improved ICERs compared to our own
findings. In testing our own model we sought to repro-
duce the findings of the NICE model by incorporating
the improved effectiveness of ERS. Despite slight differ-
ences in the modelling approach it produced relatively
consistent findings. Whilst we have based our approach
to modelling the cost-effectiveness of ERS on the model
structure used by NICE, we believe that the meta-analy-
sis of effectiveness used in the current economic analysis
has resulted in more robust input data and ultimately
more accurate estimates of the cost-effectiveness of ERS
[10].
However, all of the studies reported above suggest that
ERS is associated with only small mean differences in
lifetime costs and benefits, giving rise to the resulting
ICER being very sensitive to small changes in the rela-
tive risk of becoming physically active, together with
small changes in other data inputs. This highlights the
main limitation of this research, namely the limited evi-
dence to show that ERS has a significant and lasting
effect on participation in physical activity. Related to
this, the model assumed that the active state last long
enough to enable health benefits to be obtained and this
could not be addressed in the sensitivity analysis due
lack of data and the type of model used. Decision analy-
tic models may not be well suited to interventions
which involve complex behaviour change components.
Individual level simulation models which can detect
changes in individual behaviours over time may better
Anokye et al. BMC Public Health 2011, 11:954
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address cost effectiveness. However, there will always be
a trade-off between developing a simple model, which
can be populated and acknowledges its limitations ver-
sus a more complex model which may be a better repre-
sentation of reality but can only be partially populated
and may result in greater uncertainty. The fundamental
issue which needs to be addressed is improvements in
the source data on the effectiveness of ERS.
Further research is urgently required to examine the
effectiveness of ERS with a particular focus on 1) how
to motivate individuals to participate in ERS; 2) identify
sub-groups of the sedentary population who are most
able to benefit from ERS; 3) identify factors that are
likely to lead to sustained increased in physical activity
and changes in lifestyle. In the absence of robust evi-
dence on these, the economic case for ERS remains
encouraging but ultimately equivocal.
Conclusions
This study examines the cost-effectiveness of ERS in
promoting physical activity compared to usual care in a
primary care setting. Using a cost utility analysis frame-
work, the study uses previous research as a point of
departure, and builds on this through use of evidence
synthesis and through further analysis of the cost-effec-
tiveness of ERS in individuals with pre-existing condi-
tions, which is intended to reflect the use of ERS in
practice in the UK. ERS is associated with modest
increase in lifetime costs and benefits. Compared to
usual care, the base-case ICER for ERS was £20,876/
QALY in sedentary individuals with at least one lifestyle
risk factor and £14,618/QALY in sedentary obese indivi-
duals, £12,834/QALY in sedentary hypertensives and
£8,414/QALY for sedentary individuals with depression.
However, cost-effectiveness of ERS is highly sensitive to
small changes in the effectiveness and cost of ERS and
is subject to some significant uncertainty mainly due to
limitations in the clinical effectiveness evidence base.
Therefore, further research on the clinical effectiveness
of ERS is strongly recommended.
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